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Abstract
Although antibiotics from different classes are frequently prescribed in combination to prevent the development of
resistance amongst Cystic Fibrosis (CF) respiratory pathogens, there is a lack of data as to the efficacy of this approach. We
have previously shown that a 4:1 (w/w) combination of fosfomycin and tobramycin (F:T) has excellent activity against CF
pathogens with increased activity under physiologically relevant anaerobic conditions. Therefore, the aim of this study was
to determine whether F:T could delay or prevent the onset of resistance compared to either fosfomycin or tobramycin alone
under aerobic and anaerobic conditions. The frequency of spontaneous mutants arising following exposure to fosfomycin,
tobramycin and F:T was determined for clinical Pseudomonas aeruginosa and MRSA isolates under aerobic and anaerobic
conditions. The effect of sub-inhibitory concentrations of fosfomycin, tobramycin and F:T on the induction of resistance was
also investigated, with the stability of resistance and fitness cost associated with resistance assessed if it developed. P.
aeruginosa and MRSA isolates had a lower frequency of spontaneous mutants to F:T compared to fosfomycin and
tobramycin under both aerobic and anaerobic conditions. There was a maximum two-fold increase in F:T MICs when P.
aeruginosa and MRSA isolates were passaged in sub-inhibitory F:T for 12 days. In contrast, sequential resistance to
fosfomycin and tobramycin developed quickly (n = 3 days for both) after passage in sub-inhibitory concentrations. Once
developed, both fosfomycin and tobramycin resistance was stable and not associated with a biological fitness cost to either
P. aeruginosa or MRSA isolates. The results of this study suggest that F:T may prevent the development of resistance
compared to fosfomycin or tobramycin alone under aerobic and physiologically relevant anaerobic conditions. F:T may be a
potential treatment option in CF patients chronically colonised by MRSA and/or P. aeruginosa.
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Introduction
Resistance to antimicrobial agents is currently one of the major
problems in the healthcare setting worldwide, with changes from
susceptible to more resistant bacterial populations occurring as an
evolutionary response to antibiotic usage [1]. Antibiotic resistance
is particularly problematic in the treatment of chronic respiratory
infection in Cystic Fibrosis (CF), the major cause of morbidity and
mortality in this patient population [2]. Antimicrobial resistance is
potentiated in CF patients due to the extensive use of antimicrobial
agents from a young age, both for the prophylaxis and treatment
of respiratory infection. The net result of this high antimicrobial
usage is the sequential development of resistance to antibiotics
amongst CF pathogens [3], with approximately 25–45% of CF
patients now colonised with multidrug resistant (MDR) bacteria
[4,5]. It is also now widely recognised that the CF lung contains
anaerobic regions, with these regions supporting the growth of
obligate and facultative anaerobes [6–9]. Anaerobiosis can reduce
the activity of some classes of antimicrobials such as the
aminoglycosides leading to further problems with appropriate
antimicrobial treatment selection [10,11].
One potential strategy to prevent the development of resistance
and to improve treatment outcome is to use a combination of two
or more antimicrobials from different classes, especially if these
antibiotics have a different mechanism of action. Antibiotics are
routinely used in combination to treat CF lung infection [12];
however, data on the ability of these combinations to prevent the
development of resistance is limited and the effect of anaerobic
conditions on the development of resistance amongst CF
pathogens has not been determined.
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We have previously shown that a 4:1 combination (w/w) of
fosfomycin and tobramycin (F:T) has excellent in vitro activity
against MRSA and P. aeruginosa and importantly also has increased
activity under physiologically relevant anaerobic conditions [13].
The aim of this study was to determine if the combination of
fosfomycin and tobramycin in F:T could prevent the onset of
spontaneous and induced resistance in P. aeruginosa and MRSA
isolates from CF patients under aerobic and anaerobic conditions.
In addition, we aimed to determine if the development of
fosfomycin, tobramycin or F:T resistance was associated with a
biological fitness cost in P. aeruginosa and MRSA isolates.
Methods
Bacterial isolates
Five clinical P. aeruginosa and five clinical MRSA isolates were
used in this study. P. aeruginosa isolates were cultured from sputum
samples collected from adult CF patients at the CF centre (Belfast,
UK). MRSA isolates were cultured from bronchoalveolar lavage
fluid collected from paediatric patients attending the University of
North Carolina CF Centre (Chapel Hill, USA). In addition, P.
aeruginosa strain ATCC 27853 and S. aureus strain ATCC 29213
were used as controls for susceptibility testing and were also used
in spontaneous mutation frequency studies. Susceptibility (Mini-
mum Inhibitory Concentration, MIC) of these strains as deter-
mined previously [13] is shown in Table 1.
Antibiotics and reagents
Fosfomycin disodium was purchased from Ecros (Barcelona,
Spain) and tobramycin sulphate was purchased from Chonqing
Imperial Biochem (Chongqing, China) with both antibiotics
United States Pharmacopeia (USP) grade. F:T consisted of a 4:1
(w/w) ratio of fosfomycin and tobramycin, with F:T concentration
expressed as a combination of both antibiotics (e.g.20 mg/L F:T
= 16 mg/L fosfomycin +4 mg/L tobramycin). Mueller Hinton
agar (MHA, Oxoid Ltd, Basingstoke, UK ) and Mueller Hinton
broth (MHB; Oxoid Ltd, Basingstoke, UK) were supplemented
with 1% (w/v) potassium nitrate (KNO3, Sigma-Aldrich, Gilling-
ham, UK). when testing P. aeruginosa to act as the terminal electron
receptor and allow for anaerobic respiration. Glucose-6-Phosphate
(G6P, Sigma-Aldrich, Gillingham, UK) was added to the media at
a final concentration of 25 mg/L for all experiments. Anaerobic
conditions were achieved using an anaerobic workstation (Whitley
A35 Anaerobic workstation, Don Whitley Scientific, Shipley, UK).
Minimum Inhibitory Concentration (MIC) testing
MIC testing was carried out using the agar dilution method, as
described previously [13], with doubling dilutions in the following
antibiotic concentration ranges used: tobramycin, 0.125–32 mg/
L; fosfomycin, 0.5–256 mg/L and F:T, 0.625–320 mg/L. Isolates
were then classified as sensitive, intermediate or resistant to
fosfomycin and tobramycin according to the Committee for
Laboratory Standards Institute (CLSI) breakpoints (Fosfomycin;
#64 mg/L sensitive, 128 mg/L intermediate, $256 mg/L resis-
tant. Tobramycin; #4 mg/L sensitive, 8 mg/L intermediate,
$16 mg/L resistant) [14]. As no breakpoints are reported by
the CLSI for P. aeruginosa or MRSA with fosfomycin, those
provided for Enterobacteriaceae were used.
Spontaneous mutation frequency
The frequency of spontaneous mutants arising with increased
fosfomycin, tobramycin and F:T MICs was determined for five
clinical and one reference P. aeruginosa isolate and for five clinical
MRSA and one reference Staphylococcus aureus isolate using a
method modified from that described by MacLeod et al [15].
Briefly, isolates were inoculated in duplicate into 10 mls MHB
with one aliquot incubated under aerobic conditions and one
aliquot incubated under anaerobic conditions at 37uC. After
growth to late log phase (108–109 cfu/ml), 100 mls of each culture
was spread onto the surface of MHA plates containing fosfomycin,
tobramycin and F:T at 26, 46 and 86 the MIC for each isolate.
In addition, appropriate dilutions of each culture were plated onto
antibiotic free MHA plates to determine the number of viable cells
in the initial inoculum. After incubation at 37uC for 48 hours, the
frequency of spontaneous mutants was calculated by dividing the
number of colonies growing on the antibiotic containing plates by
the number of viable cells. Fosfomycin, tobramycin and F:T MICs
of representative mutant isolates (n = 9) selected on fosfomycin and
tobramycin plates were determined as above and compared to that
of the parent strain.
Induction of resistance
Development of resistance after serial exposure to fosfomycin,
tobramycin and F:T was determined for 3 clinical P. aeruginosa
(AY4, W050, CF35) and 3 clinical MRSA (CFP8, M6, 25A)
isolates. Isolates were inoculated into 10 mls MHB in duplicate,
with one aliquot incubated under aerobic conditions and one
aliquot incubated under anaerobic conditions at 37uC. The
Optical Density (OD550nm) of the bacterial culture was adjusted to
0.15 (approx 16108 cfu/ml) after overnight growth and 50 ml was
added to MHB containing sub-inhibitory concentrations of
fosfomycin, tobramycin and F:T (determined by growth curves,
see Table S1 for concentrations) and control (no antibiotics
added). The cultures were incubated overnight and this process
was repeated daily for 12 days, standardising the inoculum to an
OD550nm of 0.15 and using the same antibiotic concentrations for
each passage. Susceptibility testing was carried out after every 3
passages using the agar dilution method as described above, with
the culture adjusted to OD550nm 0.15 used as the initial inoculum.
After 12 days, those isolates which had developed resistance to any
of the antibiotics tested were passaged in antibiotic free broth for a
further 12 days with MICs tested after every 3 passages. For each
Table 1. Fosfomycin, tobramycin and F:T MICs for MRSA and
P. aeruginosa strains used in this study.
Isolate Species
Aerobic MIC
(mg/L)
Anaerobic MIC
(mg/L)
Fof Tob F:T Fof Tob F:T
CF35 P. aeruginosa 8 4 20 16 16 20
P3 P. aeruginosa 16 4 10 8 16 20
CA6 P. aeruginosa 256 16 40 8 32 10
W050 P. aeruginosa 4 2 10 4 16 10
AY4 P. aeruginosa 8 4 10 16 16 2.5
27853 P. aeruginosa 4 1 5 4 4 5
25A MRSA 8 0.5 5 1 2 5
CFP8 MRSA 2 0.5 5 1 4 2.5
CFP13 MRSA 1 1 5 1 4 2.5
M6 MRSA 8 0.5 2.5 2 4 1.25
M10 MRSA 8 1 2.5 4 8 5
29213 MRSA 4 0.5 2.5 0.5 32 2.5
doi:10.1371/journal.pone.0069763.t001
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isolate, the MICs of the control were tested at days 1 and 12 to
ensure passage alone had no effect on MIC.
Fitness Cost
The fitness cost associated with the development of fosfomycin
or tobramycin resistance was determined by comparing the
growth of the resistant isolate with that of the susceptible parent
isolate using growth curves. Overnight cultures were adjusted to
an OD550nm of 0.15 in MHB, further diluted 1:10 and 50 ml added
to a total volume of 20 mls MHB. Bacterial cultures were then
incubated under aerobic and anaerobic conditions and total viable
counts determined after 0, 1, 2, 4, 6 and 24 hours.
Results
Frequency of spontaneous P. aeruginosa and MRSA
mutants with elevated MICs is lower with F:T than
fosfomycin or tobramycin alone
For P. aeruginosa isolates (n = 6), the frequency of spontaneous
mutants was lower following exposure to F:T compared to
fosfomycin and tobramycin alone under both aerobic and
anaerobic conditions as summarised in Table 2 (see Table S2
for full results). The frequency of mutants on exposure to F:T was
below the detectable limit in 31/36 (86%) experiments performed
(n = 6 isolates at 26,46 and 86 MIC under both aerobic and
anaerobic conditions). In contrast, the frequency of P. aeruginosa
mutants to fosfomycin and tobramycin was below the limit of
detection in only 3/36 (8%) and 15/36 (42%) experiments,
respectively. P. aeruginosa isolates exhibited lower frequency of
mutants to fosfomycin under anaerobic (average 4.6161026 at 86
MIC) compared to aerobic conditions (average 2.2461025 at 86
MIC) whereas, frequency of mutants to F:T and tobramycin were
similar under both conditions.
MRSA isolates (n = 6) also had a lower frequency of
spontaneous mutants following exposure to F:T compared to
fosfomycin and tobramycin under both aerobic and anaerobic
conditions (Table F:T 2 and Table F:T S3, for full results). The
frequency of mutants on exposure to F:T was below the
detectable limit in 32/36 (89%) experiments. In contrast, the
frequency of MRSA mutants to fosfomycin and tobramycin was
below the limit of detection in only 15/36 (42%) and 6/36 (17%)
experiments, respectively. MRSA isolates had lower mean
frequency of mutants to fosfomycin under anaerobic (average
3.5761028 at 86 MIC) as compared to aerobic conditions
(average 2.7861025 at 86 MIC) whereas the frequency of
mutants to tobramycin MICs was higher under anaerobic
(average 1.0461026 at 86MIC) compared to aerobic (average
5.5961027 at 86MIC) conditions.
Spontaneous P. aeruginosa and MRSA mutants resistant
to fosfomycin or tobramycin alone did not have elevated
F:T MICs
Spontaneous mutant isolates which developed resistance
following exposure to fosfomycin or tobramycin did not show
any increase in F:T MIC under either aerobic or anaerobic
conditions indicating that isolates resistant to either agent alone
were not cross resistant to the combination (see Table S4).
F:T MICs did not increase when P. aeruginosa and MRSA
isolates were passaged in sub-inhibitory concentrations
of F:T
P. aeruginosa (n = 3) and MRSA (n= 3) isolates were passaged in
sub-inhibitory concentrations of fosfomycin, tobramycin and F:T
to determine if resistance could be induced by antibiotic
exposure. Results for representative P. aeruginosa and MRSA
isolates shown in figures 1 and 2, respectively, with all results
shown in Table S5. P. aeruginosa isolates exhibited no increase in
F:T MIC after passage in sub-inhibitory F:T under both aerobic
and anaerobic conditions; however, there was a 4-fold increase in
the tobramycin MIC of one of the isolates when grown in sub-
inhibitory F:T under aerobic conditions. When grown in sub-
inhibitory fosfomycin, 2/3 and 1/3 P. aeruginosa isolates
developed resistance under aerobic and anaerobic conditions,
respectively. When grown in sub-inhibitory tobramycin, 1/3 P.
aeruginosa isolates developed resistance under aerobic conditions.
Under anaerobic conditions, all three P. aeruginosa isolates were
classified as resistant to tobramycin prior to antibiotic exposure
and remained resistant to tobramycin during passage in sub-
inhibitory antibiotics.
Following passage in sub-inhibitory F:T, 1/3 and 3/3 MRSA
isolates demonstrated a 2-fold increase in F:T MIC under aerobic
and anaerobic conditions, respectively. Fosfomycin MIC increases
of 4–64 fold and 64–128 fold were also observed under aerobic
and anaerobic conditions, respectively; however, none of the
isolates post-exposure were categorised as resistant to fosfomycin.
All 3 MRSA isolates developed resistance to fosfomycin when
grown in sub-inhibitory fosfomycin under aerobic conditions and
although MICs did increase from 32- to 64-fold under anaerobic
conditions, isolates were not categorised as resistant to fosfomycin.
When grown in sub-inhibitory tobramycin, 1/3 and 2/3 MRSA
isolates developed resistance under aerobic and anaerobic
conditions, respectively.
Induced tobramycin and fosfomycin resistance is stable
after removal of antibiotic pressure and not associated
with an in vitro biological fitness cost
P. aeruginosa and MRSA isolates which developed resistance to
fosfomycin (n = 7; 3 P. aeruginosa, 4 MRSA) or tobramycin (n = 6; 3
Table 2. Meana (S.D.) frequency of spontaneous MRSA (n = 6)
and P. aeruginosa (n = 6) mutants with increased fosfomycin
(FOF), tobramycin (TOB) and F:T MICs under aerobic and
anaerobic conditions at 26, 46 and 86MIC.
Drug Aerobic Anaerobic
26MIC 46MIC 86MIC 26MIC 46MIC 86MIC
P. aeruginosa
FOF 6.6261025
(8.761025)
2.7961025
(4.661025)
2.2461025
(4.861025)
1.2361025
(1.261025)
6.8661026
(9.761026)
4.6161026
(161025)
TOB 6.7761026
(1.361025)
7.8361026
(1.561025)
3.761026
(8.961026)
4.3361025
(9.161025)
4.8361026
(4.561026)
3.0761026
(4.661026)
F:T 5.5561028
(4.861028)
5.5561028
(4.861028)
5.5561028
(4.861028)
3.1761026
(5.161026)
5.7261027
(1.361026)
2.5561028
(3.361028)
MRSA
FOF 2.8661025
(3.661025)
2.0761025
(3.161025)
2.7861025
(3.261025)
1.7361026
(3.961026)
4.5761028
(2.361028)
3.5761028
(8.261029)
TOB 1.261025
(3.761026)
3.8761026
(1.761026)
5.5961027
(5.761027)
3.1361025
(4.561025)
2.9261026
(2.961026)
1.0461026
(1.361026)
F:T 5.0561027
(6.961027)
2.7661027
(661027)
2.8861028
(7.861029)
3.5761028
(8.261029)
3.5761028
(8.261029)
3.5761028
(8.261029)
aWhere the spontaneous mutation frequency was above or below the limit of
detection, the limit of detection was used to calculate the mean e.g. if
spontaneous mutation frequency was ,4.461028 then 4.461028 was used.
doi:10.1371/journal.pone.0069763.t002
Resistance Development of CF Pathogens
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P. aeruginosa, 3 MRSA) after serial exposure to sub-inhibitory
fosfomycin or tobramycin remained resistant after 12 passages in
drug free broth. Results for representative P. aeruginosa and MRSA
isolates are shown in Figures 3 and 4, respectively. There was no
fitness cost associated with acquisition of fosfomycin or tobramycin
resistance in P. aeruginosa or MRSA isolates under either aerobic or
anaerobic conditions; this was demonstrated by no differences in
viable counts between the resistant isolates and the parent strain
over a 24 hour period, as shown in Figure 5 for representative
isolates.
Discussion
Due to the widespread use of antibiotics in the prophylaxis and
treatment of CF pulmonary infection, pathogens such as P.
aeruginosa and MRSA are becoming increasingly resistant to
conventional anti-pseudomonal and anti-staphylococcal agents.
Antibiotics are frequently used in combination in CF with the aim
of providing better coverage of target organisms and preventing or
slowing the development of antimicrobial resistance [16]; however
there is limited data on the ability of such combinations to prevent
resistance development in this setting. In the present study, we
have shown that the combination of fosfomycin and tobramycin in
F:T can prevent the onset of resistance compared to either agent
Figure 1. Fosfomycin, tobramycin and F:T MICs for P. aeruginosa isolate W050 following serial passage in sub-inhibitory antibiotic
concentrations under both aerobic and anaerobic conditions. Exposure to (A) Fosfomycin aerobic, (B) Fosfomycin anaerobic, (C) Tobramycin
aerobic, (D) Tobramycin anaerobic, (E) F:T aerobic, (F) F:T anaerobic. Filled circle (N) Fosfomycin MIC; filled square (&) Tobramycin MIC; filled triangle
(m)F:T MIC.
doi:10.1371/journal.pone.0069763.g001
Resistance Development of CF Pathogens
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alone in clinical CF P. aeruginosa and MRSA isolates. This study is
also the first to investigate the effect of anaerobic conditions on the
development of resistance by CF pathogens with resistance
development to both fosfomycin and F:T less likely under
anaerobic conditions.
Both P. aeruginosa and MRSA had a lower frequency of
spontaneous mutants to F:T compared to fosfomycin or tobra-
mycin alone, with spontaneous mutants to F:T also less likely to
arise under physiologically relevant anaerobic conditions. The low
spontaneous mutation frequencies observed with F:T indicate that
the development of resistance by spontaneous mutation to this
combination is unlikely. Two previous studies also showed that P.
aeruginosa and S. aureus had a low mutation frequency to a
combination of fosfomycin and tobramycin under aerobic
conditions, making the emergence of resistance unlikely [15,17].
Similarly, a decrease in both mutation frequency and development
of resistance has also been reported for P. aeruginosa and MRSA
when fosfomycin was combined with other antibiotics such as
linezolid, perfloxacin, ciprofloxacin and amikacin [17–19].
In contrast to F:T, both P. aeruginosa and MRSA isolates had
high mutation frequencies to fosfomycin and tobramycin alone
under both aerobic and anaerobic conditions. These results are
consistent with previous studies which have shown that Gram
negative pathogens such as Escherichia coli have high mutation
frequencies against fosfomycin [20,21]. Similarly, MacLeod et al.
also demonstrated that both MRSA and P. aeruginosa had high
mutation frequencies against both fosfomycin and tobramycin
under aerobic conditions [15]. The high mutation frequencies of
these pathogens to fosfomycin and tobramycin indicate that
resistance development would be extremely likely if these agents
were used as monotherapy to treat infections caused by P.
aeruginosa or MRSA, potentially leading to treatment failure.
In the CF lung, bacteria are often subjected to sub-lethal
concentrations of antibiotics, as the ionic CF lung environment
Figure 2. Fosfomycin, tobramycin and F:T MICs for MRSA isolate CFP8 following serial passage in sub-inhibitory antibiotic
concentrations under both aerobic and anaerobic conditions. Exposure to (A) Fosfomycin aerobic, (B) Fosfomycin anaerobic, (C) Tobramycin
aerobic, (D) Tobramycin anaerobic, (E) F:T aerobic, (F) F:T anaerobic. Filled circle (N) Fosfomycin MIC; filled square (&) Tobramycin MIC; filled triangle
(m)F:T MIC.
doi:10.1371/journal.pone.0069763.g002
Resistance Development of CF Pathogens
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reduces drug uptake and often prevents antibiotics reaching
bactericidal levels [22,23]. Induction of resistance experiments
showed that there were no more than 2-fold increases in F:T MICs
when MRSA and P. aeruginosa isolates were grown in sub-
inhibitory F:T over 12 passages under both aerobic or anaerobic
conditions. Our results are in agreement with those which
previously showed that combining tobramycin with other
antibacterial agents can delay or prevent the onset of resistance
compared to either single agent alone [24]. In contrast to F:T,
resistance to fosfomycin or tobramycin developed quickly in both
P. aeruginosa and MRSA isolates under both conditions. As
Figure 3. Fosfomycin, tobramycin and F:T MICs for P. aeruginosa
isolates following serial passage in sub-inhibitory antibiotic
concentrations and subsequent removal of antibiotic pressure
following 12 passages. (A) AY4 FOS aerobic, (B) AY4 FOS anaerobic
and (C) W050 TOB aerobic. Filled circle (N) Fosfomycin MIC; filled
square (&) Tobramycin MIC; filled triangle (m)F:T MIC; broken line,
antibiotic pressure removed.
doi:10.1371/journal.pone.0069763.g003
Figure 4. Fosfomycin, tobramycin and F:T MICs for MRSA
isolates following serial passage in sub-inhibitory antibiotic
concentrations and subsequent removal of antibiotic pressure
following 12 passages. (A) CFP8 TOB aerobic, (B) 25A TOB anaerobic,
(C) CFP8 FOF aerobic. Filled circle (N) Fosfomycin MIC; filled square (&)
Tobramycin MIC; filled triangle (m),F:T MIC, broken line, antibiotic
pressure removed.
doi:10.1371/journal.pone.0069763.g004
Resistance Development of CF Pathogens
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fosfomycin is not routinely used in the treatment of CF lung
infections, little data on fosfomycin resistance patterns amongst CF
isolates is available. However, there has been a significant increase
in the prevalence of aminoglycoside resistance in P. aeruginosa
isolated from CF patients in recent years [5]. Both intravenous
[25] and inhaled [26,27] tobramycin therapy has been associated
with a trend towards higher MICs and resistance amongst P.
aeruginosa isolates. In addition, long term tobramycin therapy has
been shown to be a risk factor for the development of multi-drug
resistant P. aeruginosa in CF [28]. The increased prevalence of
aminoglycoside resistance in CF and the speed at which resistance
to tobramycin developed in the current study may be due to the
fact that sub-lethal concentrations of aminoglycosides, such as
tobramycin, induce mutagenesis in P. aeruginosa in vitro [22]. Our
results suggest that if tobramycin or fosfomycin were to be used
alone, sub-lethal concentrations in sputum would drive resistance,
thus highlighting the importance of using the combination of
fosfomycin and tobramycin in F:T to prevent the development of
resistance. In agreement with our findings, Trapnell et al. have
recently shown, in a clinical trial, that when Fosfomycin:
Tobramycin for Inhalation (FTI) was used with P. aeruginosa
positive CF patients, there was no increase in fosfomycin,
tobramycin or FTI MICs (MIC50 and MIC90) following 28 days
treatment [29].
While the results of the current study have shown that resistance
to both fosfomycin and tobramycin developed quickly in vitro, it is
unclear whether there is always a correlation between in vitro and in
vivo resistance development. A recent review [30] concluded that
there is a lack of correlation between in vitro development of
fosfomycin resistance in E. coli and in vivo resistance development;
however, the review also concluded that development of resistance
was more likely for P. aeruginosa. Lack of correlation between in vitro
and in vivo resistance has traditionally been attributed to a
biological fitness cost associated with the acquisition of resistance
[31]. Fitness cost is an important determinant of the ability of the
mutant bacteria to survive and propagate in a given biological
niche, with the frequency of a resistant mutant in a bacterial
population being inversely proportional to the fitness cost it carries
[32]. Our results indicate that there is no fitness cost associated
with the development of fosfomycin or tobramycin resistance in P.
aeruginosa or MRSA isolates under either aerobic or anaerobic
conditions. This suggests that isolates resistant to fosfomycin or
tobramycin would have the ability to survive and propagate in the
CF lung in vivo, potentially leading to treatment failure if these
agents were used as monotherapy. Similarly, it has been reported
that there is no fitness cost associated with fosfomycin resistance in
P. aeruginosa isolates under aerobic conditions in an in vivo acute
mice lung infection model [33]. Furthermore, our results indicate
that acquired fosfomycin or tobramycin resistance is stable in these
pathogens and remains even after the removal of antibiotic
pressure. This suggests that these resistant isolates would persist in
the CF lung and would continue to be recalcitrant to fosfomycin or
tobramycin therapy.
Isolates which developed resistance to either fosfomycin or
tobramycin alone did not have elevated F:T MICs indicating that
the combination remained effective against isolates resistant to
Figure 5. Growth curves showing total viable counts of parent MRSA and P. aeruginosa isolates and resistant mutants which
developed following exposure to fosfomycin and tobramycin. (A) MRSA CFP13, aerobic, (B) MRSA CFP13 anaerobic, (C) P. aeruginosa W050
aerobic and (D) P. aeruginosa W050 anaerobic. Filled circle (N) Parent strain; filled square (&) Fosfomycin resistant mutant; filled triangle (m)
Tobramycin resistant mutant.
doi:10.1371/journal.pone.0069763.g005
Resistance Development of CF Pathogens
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either antibiotic alone. This finding and the fact that resistance to
F:T did not develop may be due to the different modes of action of
fosfomycin and tobramycin. Fosfomycin inhibits an early step in
peptidoglycan synthesis in the bacterial cell wall whereas
tobramycin primarily exerts its effect on the bacterial ribosome.
It is generally accepted that bacteria are less likely to develop
resistance to two agents with different modes of action as this will
require two separate mutational events, conferring resistance to
each antibiotic. It has also recently been shown that, under aerobic
conditions, fosfomycin enhances the uptake of tobramycin
resulting in increased inhibition of protein synthesis and bacterial
killing [34]. This interaction between the two antibiotics may also
explain why isolates resistant to either agent are not resistant to the
combination; for example, mutations conferring resistance to
fosfomycin may not prevent it acting in synergy to increase
intracellular levels of tobramycin.
In conclusion, the results of this study suggest that F:T may
prevent the development of resistance compared to fosfomycin or
tobramycin alone under aerobic and physiologically relevant
anaerobic conditions. As such, F:T may be a promising treatment
for CF patients colonised by P. aeruginosa or MRSA isolates,
particularly for use as a chronic maintenance therapy due to the
low likelihood of resistance development.
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